Kazia Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

John Friend

Chief executive officer

AU$1.6m

Total compensation

CEO salary percentage	47.1%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Friend's remuneration changed compared to Kazia Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	AU$2m	AU$743k	-AU$20m
Mar 31 2023	n/a	n/a	-AU$23m
Dec 31 2022	n/a	n/a	-AU$25m
Sep 30 2022	n/a	n/a	-AU$25m
Jun 30 2022	AU$1m	AU$430k	-AU$25m

Compensation vs Market: John's total compensation ($USD1.03M) is above average for companies of similar size in the Australian market ($USD295.83K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Friend (53 yo)

less than a year

Tenure

AU$1,576,913

Compensation

Dr. John E. Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Medic...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Friend	CEO, MD & Interim Chairman	less than a year	AU$1.58m	no data
Karen Krumeich	Chief Financial Officer	1.8yrs	AU$1.05m	no data
Anna Sandham	Company Secretary	less than a year	no data	no data

0.8yrs

Average Tenure

Experienced Management: KZA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
John Friend	CEO, MD & Interim Chairman	less than a year	AU$1.58m	no data
Bryce Carmine	Independent Non-Executive Director	8.4yrs	AU$94.00k	0.36% A$ 68.5k
Patrick Wen	Member of Scientific Advisory Board	1.3yrs	no data	no data
Steven Coffey	Independent Non-Executive Director	11yrs	AU$94.00k	0.42% A$ 79.4k
Ebru Davidson	Director	less than a year	AU$7.12k	no data
Priscilla Brastianos	Member of Scientific Advisory Board	1.3yrs	no data	no data
John de Groot	Member of Scientific Advisory Board	1.3yrs	no data	no data
Alan Olivero	Member of Scientific Advisory Board	1.3yrs	no data	no data

1.3yrs

Average Tenure

61yo

Average Age

Experienced Board: KZA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Kazia Therapeutics Management

Management criteria checks 0/4

Key information

Recent management updates

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Recent updates

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

New major risk - Market cap size

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

New minor risk - Share price stability

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Forecast to breakeven in 2024

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications

Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801

No longer forecast to breakeven

Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma

Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia

Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022

No longer forecast to breakeven

Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy

No longer forecast to breakeven

Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study

Kazia Therapeutics Limited Launches New Scientific Advisory Board

Kazia Therapeutics Limited Launches New Scientific Advisory Board

United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort

Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference

Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO

Insufficient new directors

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion

Kazia Presents Preclinical Data for Paxalisib At AACR

Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient

Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Non-Executive Director recently bought AU$54k worth of stock

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited

Kazia Releases Final Data from P2 Paxalisib Trial

No longer forecast to breakeven

Forecast to breakeven in 2023

Full year 2021 earnings released: AU$0.072 loss per share (vs AU$0.17 loss in FY 2020)

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs

Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories

Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial

Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Kazia Therapeutics Limited announced that it expects to receive AUD 5.2 million in funding from Simcere Pharmaceutical Group Limited

Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB

New 90-day high: AU$1.46

Kazia Therapeutics Limited Announces GBM AGILE Pivotal Study Commences Recruitment to Paxalisib Arm

CEO, MD & Executive Director recently bought AU$53k worth of stock

Kazia Therapeutics Limited to Collaborate with Pacific Pediatric Neuro-Oncology Consortium for New Paxalisib Combination Study in DIPG

Kazia Therapeutics Limited Announces Top-Line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

Kazia Therapeutics Limited Presents Further Paxalisib Data At SNO, Confirming Earlier Positive Safety and Efficacy Signals in Glioblastoma

New 90-day high: AU$1.18

Annual earnings released: Revenue misses expectations

Kazia Therapeutics Limited Executes Agreement to Commence GBM Agile Pivotal Study

Kazia Therapeutics Limited Enters into Collaboration with Dana-Farber Cancer Institute in the United States to Investigate the Use of Kazia’S Investigational New Drug, Paxalisib

Kazia Therapeutics Limited Enter New Collaboration with Dana-Farber Cancer Institute